Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.52 |
| ▸ | PDE4A | P27815 | 14/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701700 | 0.94 | UTS2R (0.43) | PDE4BPDE4CPDE4APDE4D | |
| SCHEMBL6025567 | 0.89 | PDE4B (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL16702165 | 0.87 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1583109 | 0.87 | PDE4B (0.66) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5191733 | 0.86 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5423831 | 0.85 | PDE4B (0.55) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825653 | 0.84 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5191578 | 0.83 | PDE4A (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6870187 | 0.83 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL10325021 | 0.82 | PDE4B (0.54) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015175956-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015069711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-2583098-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2555769-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | Celgene Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011159750-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011127019-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |